nadofaragene firadenovec
nadofaragene firadenovec: 3 clinical trials tracked.
nadofaragene firadenovec evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
What is verified about nadofaragene firadenovec, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (3)
A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Primary endpoint: Recurrence Free survival
A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
Primary endpoint: Complete response
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
Primary endpoint: Whether or not a patient with CIS (with or without concomitant high-grade Ta or T1 papillary disease) achieves Complete Response (CR) at first evaluation from first ADSTILADRIN instillation